MedTrace Logo

A Study of SBRT for Squamous Cell Carcinoma of the Head and Neck

NCT04435938 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2020-12-02

No results posted yet for this study

Summary

To evaluate the tumour response rate of squamous cell carcinoma of the head and neck following stereotactic body radiotherapy (SBRT) of 45Gy in 5 fractions delivered once every 3-4 days, such that treatment is completed within 15 days.

Conditions

Interventions

RADIATION

Stereotactic Body Radiotherapy (SBRT)

45 Gy in 5 fractions delivered once every 3-4 days

Sponsors & Collaborators

Principal Investigators

  • Justin Lee, MD · Juravinski Cancer Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-10
Primary Completion
2022-06-30
Completion
2022-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04435938 on ClinicalTrials.gov